Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Participants needed: 178
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Alto NeuroscienceUpdated: Apr 28, 2026Locations: 48
Eligibility criteria

Male and female participants, ages 18 to 75 years, inclusive, at the time of sig... [+3]

Evidence of unstable medical condition [+6]

Read more
Status: Recruiting

Study of ALTO-101 in Patients With Schizophrenia

This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.

Participants needed: 82
Trial details
Phase: Phase 2Age: 21-55Biological sex: AllType: InterventionalSponsor: Alto NeuroscienceUpdated: Dec 26, 2025Locations: 14
Eligibility criteria

Schizophrenia diagnosis for at least one year [+5]

Evidence of unstable medical condition [+5]

Read more
Status: Recruiting

Study of ALTO-300 in MDD

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Participants needed: 321
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Alto NeuroscienceUpdated: Jul 24, 2025Locations: 45
Eligibility criteria

Have a diagnosis of moderate to severe major depressive disorder (MDD) [+3]

Evidence of unstable medical condition [+5]

Read more
Status: Recruiting

ALTO-100 in Bipolar Disorder With Depression (BD-D)

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Alto NeuroscienceUpdated: Jul 16, 2025Locations: 27
Eligibility criteria

Have a diagnosis of BD-I or BD-II as well as BD-D [+3]

Evidence of unstable medical condition [+5]

Read more